Oct 31, 2016 by David Liang2 Beaten-Up Biotech Blue Chip Stocks on Sale TodayFresh off better-than-expected Q3 earnings, are Bristol-Myers and Celgene still bargains?
Oct 19, 2016 by David Liang3 Reasons Bristol-Myers Is a BuyIs Opdivo on track to Opd-imize your portfolio?
Oct 19, 2016 by David LiangThe Holy GRAIL of Healthcare? Illumina Eyes Up A Potential $200 Billion MarketLiquid biopsy technology could represent a stage shift within the paradigm of cancer treatment.
Oct 10, 2016 by David LiangBetter Buy: Biogen vs. CelgeneCelgene is looking to move into Biogen's multiple sclerosis empire. See which one of these biotech behemoths is the better choice for your portfolio.
Oct 1, 2016 by David LiangCelgene Is Building an Autoimmune Empire -- and No One Is Talking About ItHas Celgene been quietly building up an autoimmune powerhouse?
Sep 28, 2016 by David LiangWill Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis?While Celgene looks to move into the MS space, Biogen isn't going down without a fight
Sep 21, 2016 by David LiangThe Most Exciting Drug in Celgene's PipelineCelgene's ozanimod could stand head and shoulders above the competition.
Sep 15, 2016 by David Liang5 Reasons Celgene Is a BuyThe combination of a rich collaborations pipeline and a discount to growth make Celgene a fantastic long-term holding.
